16 November 2023 - Today, the FDA approved capivasertib (Truqap, AstraZeneca Pharmaceuticals) with fulvestrant for adult patients with hormone receptor ...
16 November 2023 - Today, the FDA approved pembrolizumab (Keytruda, Merck) with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment ...
15 November 2023 - The approval is based on the pivotal TRIDENT-1 trial, in which Augtyro successfully achieved a high objective ...
15 November 2023 - The US FDA has approved Defencath (taurolidine and heparin) catheter lock solution to reduce catheter-related bloodstream infections ...
9 November 2023 - Today, the US FDA approved Ixchiq, the first chikungunya vaccine. ...
9 November 2023 - Today, the US FDA approved Adzynma, the first recombinant protein product indicated for prophylactic or on demand ...
9 November 2023 - On 7 November 2023, the FDA revised the existing indication of pembrolizumab (Keytruda, Merck) with trastuzumab, fluoropyrimidine, ...
8 November 2023 - Fruzaqla is the first targeted therapy approved for metastatic colorectal cancer regardless of biomarker status or ...
8 November 2023 - Today, the US FDA approved Zepbound (tirzepatide) injection for chronic weight management in adults with obesity (body ...
6 November 2023 - The company received final approval from the US FDA for its new drug application for Zituvimet ...
1 November 2023 - Voqeuenza met the primary endpoints and key secondary superiority endpoints in the pivotal Phase 3 PHALCON-EE trial ...
31 October 2023 - Sugemalimab is the world’s first anti-PD-1/PD-L1 monoclonal antibody approved for relapsed or refractory extranodal NK/T-cell lymphoma indication. ...
1 November 2023 - On 31 October 2023, the FDA approved pembrolizumab (Keytruda, Merck) to be used with gemcitabine and cisplatin ...
31 October 2023 - Today, the US FDA approved Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Stelara (ustekinumab) ...
31 October 2023 - FDA approval based on robust Phase III data in which Cosentyx (secukinumab) showed rapid relief from symptoms ...